Skip Navigation

JNCI Journal of the National Cancer Institute 1999 91(7):585-587; doi:10.1093/jnci/91.7.585
© 1999 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Roemer, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Roemer, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 91, No. 7, 585-587, April 7, 1999
© 1999 Oxford University Press

NEWS

Bullish Sentiment Stays (Mostly) High for Investments in Cancer Drugs and Biotechnology

Jennifer Roemer

With worldwide oncology drug sales expected to nearly double from $7.84 billion in the year 2000 to more than $13 billion in 2005, participants in a recent New York Society of Security Analysts' meeting in New York were largely bullish about the benefits of investing in oncology drugs and biotechnology. But there were some who were bearish as well.

The meeting touched on current cancer news, along with the risks and benefits of investing in new cancer agents. The main purpose of the conference, sponsored by the not-for-profit educational organization NYSSA, was to provide "not only . . . [Full Text of this Article]

Blockbuster Drugs

Tapping the Source


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?